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1. Introduction
  Worldwide, there were 8.8 million new cases of active 
tuberculosis (TB) and an estimated 1.7 million deaths from 
TB in 2003[1]. India occupies only 2% of the land area 
and 15% of the total population but shares 30% of the TB 
burden. One person dies from TB in India every minute, 
more than 1 000, every day and 500 000 every year[2]. 
Sputum smear for acid fast bacilli (AFB) is the primary 
microbiologic method for diagnosis of TB. Culture for 
AFB requires more time, trained personal and laboratory 
facilities. Human immunodeficiency virus (HIV) co-
infection can further complicate TB diagnosis with atypical 
clinical symptoms of pulmonary tuberculosis (PTB) and a 
higher likelihood of negative sputum smears for AFB[3]. TB 
is an important opportunistic disease among HIV infected 
persons world wide. In developing countries of Africa, 
Southeast Asia & Latin America an estimated 10 millions 
persons are co infected. The tuberculin skin test (TST) 
which is the standard for diagnosis of latent tuberculosis 
infection (LTBI), is the only test available for that purpose in 
resource-limited settings, and sometimes is used to aid in 
the diagnosis of active TB; however, its specificity is limited 
by cross reactivity with non tuberculous mycobacteria and 
bacille calmette-Guerin (BCG) vaccine strains of M. bovis, 
and its sensitivity can be affected by malnutrition and 
immuno-suppression[4].
  Mycobacterium tuberculosis (M. tuberculosis) infection is 
chiefly controlled by activation of macrophages through 
type 1 cytokine production by T cells (Th1), and interferon 
gamma (IFN-毭) is central to this process[5]. Patients with 
defective IFN-毭receptor develop severe mycobacterial 
disease[6]. Several ex vivo studies have focused on the role 
of IFN-毭and its regulatory cytokines in active pulmonary 
TB (PTB) patients and they suggested that cytokine analysis 
Objective: To determine the relationship of the capacity to produce interferon gamma (IFN-
毭) in whole blood, bacteriological, hematological, radiographic and clinical presentations in 
new, HIV seronegative cases of pulmonary tuberculosis (TB). Methods: 80 cases and 50 control 
subjects aged 15 years onwards, representative of Kasturba Hospital and Nursing schools of 
Wardha district of Maharashtra state in India were examined for their health condition with 
standard methodology. Results: Among these TB patients, 73.8% were Quantiferon-TB gold 
(QFT) positive with IFN-毭 concentration as 0.35 IU or more and there was none in healthy 
controls. The mean IFN-毭 concentrations varied between 9.58 IU (50-59 yrs) and 2.58 IU (曒
60 yrs), showing no trend. The differences in positivity and mean IFN-毭concentrations were 
statistically insignificant. Both the QFT positivity and IFN-毭concentrations were higher in 
normal lymphocyte percent as compared to below and above normal, but differences were not 
statistically significant. Conclusions: The IFN-毭concentrations are not correlated with any of 
the predictors of disease severity studied, the levels are significantly higher in observation group 
as compared to healthy group.
Bandyopadhyay M et al./Asian Pacific Journal of Tropical Medicine (2010)224-231 225
in whole blood cultures may be able to discriminate between 
active TB infection and healthy controls[7]. Vankayalapati[8] 
shows that Th1 (helper T-cell 1) cytokines in sputum, 
serum and bronchoalveolar lavage fluid (BALF) correlate 
with disease activity during active TB of the lung. Advances 
in genomics and immunology have led to promising 
alternative- in vitro interferon gamma release assay (IGRA), 
based on the principal that T cells of individuals infected 
with M. tuberculosis release IFN-毭 when they re-encounter 
TB specific antigens[9,10]. Newly discovered antigens that 
are specific to the M. tuberculosis complex are not produced 
by M. bovis. BCG vaccine strains offer the opportunity to 
develop IGRA with high sensitivity for TB and LTBI, and 
specificity for LTBI and potentially for TB as well[11].Three 
promising antigens for use in such assays are the 6-kDa 
early secreted antigenic target (ESAT-6), 10-kDa culture 
filtrate protein (CFP-10) , and the Rv2654 antigen (TB 7.7)[12]. 
These antigens, encoded by genes located within the region 
of difference 1 (RD1) segment of the M. tuberculosis genome, 
are more specific because they do not share with any of the 
BCG vaccine strains or certain species of non tuberculosis 
mycobacterium (NTM)[12].
  ESAT-6 and CFP-10 can elicit strong IFN-毭responses 
from T-cells of persons infected with MTB but not from 
T-cells of those vaccinated with BCG or at low risk of 
infection[11]. Although IGRAs are promising and offer 
logistic advantage, unresolved issues remain. One such is 
whether they can be used for diagnosis of active TB and for 
determining the disease severity. Effector response may be 
driven by antigen load, and there is evidence that reduction 
of the antigen load by treatment decreases T cell responses. 
  The sensitivity of IFN-毭in active PTB cases has been 
reported to be 75%-89% using TB specific antigens 
(ESAT-6, CFA-10 & TB7.7) and 96% using purified 
protein derivative (PPD)[13]. Several studies have reported 
significantly higher IFN-毭concentrations in serum[14] and 
broncho alveolar lavage fluid (BALF)[15] of active TB patients 
as compared to healthy controls. 
  Since IFN-毭production correlates strongly with ineffective 
immunity to TB, Sodhi et al[16] determined, if production 
of this cytokine varied in patients with different clinical 
manifestations of TB and observed that the radiographic 
extent of disease and the site of disease were the only 
independent predictors of IFN-毭production in HIV-negative 
and infected patients (P=0.001). It is concluded that reduced 
IFN-毭production by peripheral blood mononuclear cells 
(PBMCs) is a marker of severe TB in both HIV-negative and 
infected patients with TB. Inokuchi et al[17] in their attempt to 
determine if whole blood IFN-毭 production IS correlated with 
the radiographic extent of PTB before treatment by using 
PPD and phytohemagglutinin (PHA) for stimulation, observed 
that PHA stimulated IFN-毭production was lower in patients 
than healthy volunteers (P<0.05)  and inversely correlated 
with disease extent (P<0.01). Tuberculous PPD stimulated 
IFN-毭production, however, it did not correlate with disease 
extent. It is concluded that PPD-IFN-毭/ PHA- IFN-毭
may be useful for diagnosis of TB but not for evaluating the 
disease severity, and it is suggested that PHA-IFN-毭could 
be considered as a marker of disease severity. Tsiouris et 
al[18] suggested that TST combined with IGRA or with a single 
sputum smear may play a role in excluding the diagnosis 
of TB in some settings. IGRA with Quantiferon TB Gold 
(QFT-G) in tube kit (Cellestis Ltd Australia), which has 
been performed previously in estimating prevalence of LTBI 
among health care workers[19], study of IFN-毭responses 
among health care workers before and after LTBI preventive 
therapy and diagnosis of LTBI in children[20].
  There has been practically no study from India that 
has studied the correlation of IFN-毭response following 
stimulation of PBMCs in whole blood using In-tube IGRA 
manufactured by Cellestis Ltd, Australia, with different 
parameters suggesting disease severity in PTB patients. 
Keeping in view the above, the present study had been 
undertaken 镡 to determine if the capacity to produce IFN-
毭in whole blood is related to bacteriological, hematological, 
radiographic and clinical presentations in new, HIV 
seronegative cases of PTB; 镢 to confirm new cases of PTB 
by Zeihl Neelsen staining, culture on Lowenstein Jensen 
medium and X- ray chest; 镤 to determine HIV status of 
recruited patients using 4th generation enzyme-linked 
immunosorbent assay (ELISA) kit; 镥 to determine the disease 
severity in recruited patients through smear/culture grading 
and extent of disease by chest radiography; 镦 to determine 
total leukocyte count, absolute lymphocyte count and 
lymphocyte percent in recruited patients using automated 
coulter counter; 镧 to determine IFN-毭concentrations in 
whole blood among patients and controls using Quantiferon 
TB Gold (QFT) In tube commercial test kit; 镨 to correlate 
IFN-毭results and concentrations with smear, culture, 
symptoms suggestive of PTB, radiographic and hematological 
findings. 
2. Materials and methods
  The present work was performed in the Department 
of Microbiology, Mahatma Gandhi Institute of Medical 
Sciences, Sevagram, which is located in a rural Institute in 
Wardha district of Maharashtra state in Central India. The 
study was conducted from November 2004 to October 2005.
2.1. Study population
  A total of 80 subjects attending the Kasturba Hospital 
attached to the Institute and fulfilling the following inclusion 
criteria: 
  Adult above 15 years of age; newly diagnosed case of 
active PTB ( smear and/or culture positive and/or evidence 
of TB by chest X ray); new case having received treatment 
for no more than 4 weeks at the time of inclusion; HIV sero-
negative.
  The exclusion criteria were as following:
  Refusal to participate; unstable cardio-respiratory 
condition; past H/O active TB or those who have received 
treatment for more than one month; pregnant women; HIV 
seropositive.
  The control group included 50 healthy students of MGIMS 
& Kasturba Nursing School. All patients and controls were 
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enrolled after obtaining written informed consent. Where 
ever necessary this was done in local language. The study 
was started after obtaining the approval of the Institutes 
ethical committee.
  All patients were subjected to following studies:
2.2. Sputum smear examination by ZN method
  Three sputum specimens were examined [spot/overnight/
spot as per revised national tuberculosis control programme 
(RNTCP) criteria]. Grading of smears was done as TRC 
manual[21].
2.3. Sputum culture
  All sputum samples were inoculated on two LJ slopes and 
incubated in a CO2 incubator at 37 曟 for a maximum of 
8 weeks before declaring them negative. All slopes were 
examined weekly and the growth graded as TRC manual and 
the isolate identified by standard methods[21].
2.4. X-ray chest
 This was done for all patients and examined by two 
independent consultants blinded to laboratory results. The 
presence or absence of cavitations was noted and the extent 
of disease was assessed as follows:     
2.4.1 Minimal disease
 The total extent of disease did not involve more than an area 
of lung equivalent to that above the second chondrosternal 
junction and the spine of fourth thoracic vertebra.
2.4.2. Moderately advanced disease
  Dense and confluent lesions did not exceed an area of 
one third of the volume of one lung; non confluent lesions 
of slight or moderate density did not exceed the area of one 
lung.
2.4.3. Far advanced disease
More extensive than moderately advanced disease.
2.5. HIV status
  This was determined by 4th generation ELISA kit, 
Vironostika (BioMerieux), which is capable of detecting 
HIV-1, HIV-2 antibodies and p24 antigen. The test was 
performed as the directions of the manufacturer. 
2.6. Haemotological examination
  Total lymphocyte count (TCL) and lymphocyte percent were 
determined for all patients using coulter counter.
2.7. IFN-毭 estimation
  The main kit was QuantiFERON®-TB Gold KIT (Cellestis 
Limited, Australia). The test was performed in following 
stages.
2.7.1. Collection of blood, incubation & harvest of plasma
  Two mL blood was collected and 1 mL each was added 
to the two tubes up to the 1 mL mark: Nil Control (adjusts 
for background) and TB Antigen tube provided with the 
kit. Both tubes were shaken vigorously and incubated 
immediately upright at 37 曟 for 24 hrs.
  Following the incubation, the tubes were centrifuged at 
2 200 rpm for 5-10 minutes to harvest plasma. Movement 
of gel plugs to separate plasma from cells indicated that 
centrifugation was successful. Plasma (300-500毺L) was 
pipetted out and transferred to separate 1mL sterile micro 
tube racks in a 96 well format (two for each patient). All 
plasma samples were stored at 2-4 曟 till evaluated (4 
weeks maximum).
2.7.2. Preparation of reagents
  All reagents were prepared as kit instructions All 
plasma samples and reagents, except for Conjugate 100
伊Concentrate, were brought to room temperature (22暲
5) 曟 before use. At least 60 minutes were allowed for 
equilibration. One ELISA plate for 44 samples was used 
at one time. The standards (S1 to S4) and conjugate were 
reconstituted as kit instructions. The lay out of samples and 
controls was as Table 1. Prior to assay plasma samples were 
mixed. 50 毺L of freshly prepared diluted conjugate was 
added to all wells using a multichannel pipette. Following 
this 50 毺L of plasma was added to test 50 毺L of the four 
standards in duplicate in respective wells as per layout 
(Table 1).
  The conjugate and plasma samples/standards were 
thoroughly mixed using   microplate shaker (Waveform=20, 
amplitude=6, time=1 minute). Plate was covered with a lid 
and incubated at room temperature (22暲5) 曟 for (120暲5) 
minutes. Wells were washed with 300-400 毺L of working 
strength wash buffer forsicycles at room temperature with a 
fully automated ELISA washer. After the last washing plates 
were tapped face down on an absorbent wipe to remove 
residual wash buffer. 100 毺L of enzyme substrate solution 
was added to each well and mixed thoroughly on the shaker.
Plate was covered with a lid and incubated at room 
temperature for 30 minutes, starting from the time substrate 
was added to the first well. 50 毺L of the enzyme stop 
solution was added to each well in the same sequence and 
same speed as was the substrate added, following completion 
of incubation. The stop solution was gently mixed. Optical 
density was read within 5 minutes of terminating the 
reaction using 450 nm filter, with a reference filter between 
620 nm and 650 nm. Optical density (OD) values were used 
to calculate results. OD values were directly fed from the 
ELISA reader to the computer and the QFT-G in tube analysis 
software was used to analyze raw data and to calculate 
result. Interpretation of results shown in Table 2.
  All relevant patient related information was recorded.
2.8. Statistical analysis
  This was done using SPSS 10.0 version for Windows and 
Smart viewers software. Means were compared using the 
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Students't' test. Proportions, after converting into numbers, 
were compared using the Chi-square test and the Fisher's 
exact test, as appropriate. P<0.05 was considered as 
significant.
3. Results
  Among the TB patients, 73.7% were QFT positive with 
IFN-毭concentration as 0.35 IU or more, and there was 
none in healthy controls. The IFN-毭concentrations were 
significantly higher in patients as compared to the control 
group (P=0.015). The age of the patients included in the 
study ranged between 18 to 80 years, with the mean age 
being 37.49 years. As per the kit criteria, both positive 
and negative test results were seen in all the age groups 
studied. The positive results varied between 92.3% (< 20 
yrs) to 60.0% (30-39 yrs) and negative between 7.7% (<20 
yrs) to 40.0% (30-39 yrs). The mean IFN-毭concentrations 
varied between 9.58 IU (50-59 yrs) and 2.58 IU (曒60 yrs), 
showing no trend. The positivity (81.0%) and mean IFN-
毭concentrations (7.11 IU) were higher in the females with 
insignificant difference (Table 3).
  Table 4 showed the correlation with clinical features. 
More patients with fever showed positive results (74.7%) 
and had higher mean IFN-毭concentrations (6.82 IU) 
with insignificant difference. Patients without cough 
showed higher positivity (100.0%) but lower mean IFN-毭
concentrations (5.64 IU). However, those without cough were 
small in number. Haemoptysis is an important presentation 
of advanced disease. However, both positivity (75.0%) and 
mean IFN-毭concentrations (7.24 IU) were higher in those 
without haemoptysis with insignificant difference. Loss of 
weight was seen in 66 subjects. Those loss of weight patients 
showed higher positivity (74.2%) and lower mean IFN-毭
concentrations (6.49 IU).
  Table 5 showed the correlation with bacteriological status, 
including smear and culture. The higher the smear and/or 
culture grading the higher the severity of the disease, hence 
higher positivity and IFN-毭concentrations are expected in 
them. On correlation of smear with IFN-毭, it was observed 
that maximum positivity was seen in those with 2+ smear 
(92.9%) and there was no upward trend in positivity with 
increase in number of bacilli/mL of sputum, as those with 
1-9 bacilli in their sputum showed higher positivity (76.9%) 
than those with 3+ smears (69.2%). It was interesting to 
note that the mean IFN-毭concentration was the maximum 
in smear negative cases (15.16 IU). None of the differences 
were significant. As seen in the smear correlation, maximum 
positivity was seen in patients with 2+ culture report 
(81.8%) and there was no upward trend as expected, either 
in the positivity or mean IFN-毭concentrations with increase 
in culture grading. The lowest mean IFN-毭concentrations 
were recorded in patients with 3+ culture report. 
  The degree of damage to the lungs is determined through 
chest radiography. The greater the damage, the higher the 
extent of disease. Though, the mean IFN-毭concentrations 
were higher in those with cavity, more patients without 
cavity showed positive QFT results. None of these differences 
were statistically significant. 
  On correlating the various grades of disease severity, 
though positivity was higher in those with moderate disease, 
mean IFN-毭concentrations were found to be higher in those 
with minimal disease. However, none of these differences 
were significant (Table 6). 
  Table 7 showed the correlation of hematological findings 
with IFN-毭. On the basis of TLC counts patients were 
divided into three groups: normal counts (4 000-11 000 
cells/毺L of blood), below normal (<4 000 cells/毺L) and 
above normal (>11 000 cells/毺L). Though the positivity 
was the maximum in those having TLC>11 000, the mean 
IFN-毭concentrations were the highest in those with TLC<4 
000. None of the observations were significant. Both the 
percent positivity (68.4%) and mean IFN-毭concentrations 
(5.25 IU) were lower in those showing higher than normal 
absolute lymphocyte count (>4 500) than those with lower 
count (78.6% & 8.03 IU, respectively), but the differences 
were not significant. Both the QFT positivity and IFN-毭
concentrations were found to be higher in those having 
normal lymphocyte percent as compared to those below 
and above normal, but then these differences were not 
statistically significant. 
4. Discussion
  PTB is one of the most important infectious diseases in the 
world. Both, TB occurring in immuno-deficient patients 
and multi-drug TB have emerged as clinical problems. T 
cells play a central role in the human immune response 
to mycobacterial pathogens and the balance of T-cell 
cytokines produced in response to infection is believed to 
have a profound effect on clinical outcome. Although the 
specific cytokines that mediate immunologic resistance to 
mycobacteria in humans remains unidentified, IFN-毭appears 
to be the key cytokine involved, as increased susceptibility 
to mycobacterial infections has been reported in individuals 
with IFN-毭receptor deficiency or mutations in IFN-毭
receptor 1[6]. The primary function of this cytokine is to 
activate the macrophage and enable this cell to carry out 
its mycobacterial effecter functions. To date, the immune 
response to M. tuberculosis has been assessed by skin testing 
using the purified protein derivative from M. tuberculosis; 
however, TST measures both effecter and memory T-cell 
responses as against new generation IFN-毭assays which 
measures mostly effecter T-cell responses[22].  Both TST and 
IFN-毭assays have been used for diagnosing MTB infection, 
however, whether the results of whole blood IFN-毭assays is 
correlated with disease severity is not clear at present.
  In the present study the sensitivity of the QFT TB Gold test 
in HIV sero-negative active PTB cases was 73.7%, taking 曒 
0.35 IU/mL  IFN-毭concentration in whole blood as positive, 
as per the kit, following stimulation with TB specific 
antigens. Tsiouris et al[18] have reported an overall sensitivity 
of 75% in all and 82% in new PTB patients. Clinical studies 
have estimated the sensitivity of QFT TB Gold to be 89% 
approximately, for active TB disease. In comparison to QFT 
TB Gold, which utilizes TB specific antigens for stimulation, 
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Table 1 
Sample layout.
Row 1 2    3    4    5    6    7    8    9 10 11 12
A 1N 5N 9N 13N 17N S1 S1 25N 29N 33N 37N 41N
B 1A 5A 9A 13A 17A S2 S2 25A 29A 33A 37A 41A
C 2N 6N 10N 14N 18N S3 S3 26N 30N 34N 38N 42N
D 2A 6A 10A 14A 18A S4 S4 26A 30A 34A 38A 42A
E 3N 7N 11N 15N 19N 21N 23N 27N 31N 35N 39N 43N
F 3A 7A 11A 15A 19A 21A 23A 27A 31A 35A 39A 43A
G 4N 8N 12N 16N 20N 22N 24N 28N 32N 36N 40N 44N
H 4A 8A 12A 16A 20A 22A 24A 28A 32A 36A 40A 44A
  Note: 1N: Sample 1 Nil control plasma; 1A: Sample 1 TB specific antigen plasma; S1, S2, S3, S4: Standard controls with IFN-毭concentration: 4IU, 
1 IU, 0.25 IU and 0.1 IU, respectively.  
Table 2 
Interpretation of results.
NIL(IU/mL) TB antigen minus NIL (IU/mL) Result Interpretation
<   8.0 <  0.35
Negative M.tuberculosis infection NOT likely
>  0.35 & < 25 % of Nil value 
>  0.35 & >  25 % of Nil value Positive1 M.tuberculosis infection likely
>  8.02 Any Indeterminate 3 Results are indeterminate for TB antigen responsiveness
1 Where M. tuberculosis infection is not suspected, initially positive results can be confirmed by retesting the original plasma samples in duplicate 
in the QuantiFERON®-TB Gold ELISA. If repeat testing of one or both replicates is positive, the individual should be considered test positive.
2 In clinical studies, less than 0.25% of subjects had IFN-毭 levels of   > 8.0 IU/mL for the Nil control.
3 Refer to Trouble shooting section of the packing insert for possible causes.
Table 3 
QFT result and IFN-毭concentration in health, age and sex.
Group n
Result[n(%)] Mean concentration 
(IU)Positive Negative
Health* Healthy controls 50 Nil 50(100.0) 23.55
Patients 80 59(73.7) 21(26.3) 6.71
Age(yrs) <20 13 12(92.3) 1(7.7) 7.19
20-29 22 17(77.3) 5(22.7) 8.08
30-39 10 6(60.0) 4(40.0) 9.37
40-49 9 6(66.7) 3(33.3) 7.74
50-59 5 4(80.0) 1(20.0) 9.58
曒60 21 14(66.7) 7(33.3) 2.58
Total 80 59(73.7) 21(26.3) 6.71
Sex Male 59 42(71.2) 17(28.8) 6.57
Female 21 17(81.0) 4(19.0) 7.12
Total 80 59(73.7) 21(26.3) 6.71
  *: Significant at 1% level.
Table 4 
QFT result and IFN-毭concentration by clinical features.     
Parameters n
Result[n(%)] Mean concentration 
(IU)Positive Negative 
Fever Yes 75 56(74.7) 19(25.3) 6.82
No 5 3(60.0) 2(40.0) 5.05
Total 80 59(73.7) 21(26.3) 6.71
 Cough Yes 77 56(72.7) 21(27.3) 6.75
No 3 3(100.0) - 5.64
Total 80 59(73.7) 21(26.3) 6.71
Haemoptysis Yes 16 11(68.8) 5(31.3) 4.58
No 64 48(75.0) 16(25.0) 7.24
Total 80 59(73.7) 21(26.3) 6.71
Weight loss Yes 66 49(74.2) 17(25.8) 6.49
No 14 10(71.4) 4(28.6) 7.73
Total 80 59(73.7) 21(26.3) 6.71
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Table 5 
QFT result and IFN-毭concentration by sputum smear and culture.       
Group n
Result[n(%)] Mean concentration 
(IU)Positive Negative 
Sputum smear Negative 2 1(50.0) 1(50.0) 15.17
1-9 bacilli 13 10(76.9) 3(23.1) 6.55
1+ 38 26(68.4) 12(31.6) 6.59
2+ 14 13(92.9) 1(7.1) 9.23
3+ 13 9(69.2) 4(30.8) 3.21
Total 80 59(73.7) 21(26.3) 6.71
Culture Negative 7 4(57.1) 3(42.9) 4.94
< 20 colonies 7 4(57.1) 3(42.9) 7.47
1+ 29 21(72.4) 8(27.6) 6.37
2+ 22 18(81.8) 4(18.2) 9.53
3+ 15 12(80.0) 3(20.0) 3.69
Total 80 59(73.7) 21(26.2) 6.71
Table 6 
QFT result and IFN-毭concentration by Chest X ray positivity and grading.        
Group n
Result[n(%)] Mean concentration
 (IU)Positive Negative
X-ray positivity Not suggestive of TB 4 2(50.0) 2(50.0) 6.13
Suggestive of TB 39 26(66.7) 13(33.3) 5.87
 Suggestive of TB +  cavity 37 21(56.8) 16(43.2) 7.82
Total 80 49(73.7) 31(26.2) 6.71
X-ray grading Negative 4 2(50.0) 2(50.0) 9.71
MD 8 5(62.5) 3(37.5) 13.95
Md. D 23 18(78.3) 5(21.7) 7.13
Ad. D 45 34(75.6) 11(24.4) 5.67
Total 80 59(73.7) 21(26.3) 6.71
  M: Minimal, Md: Moderate, Ad:Advance, D:Disease, C: Cavity.
Table 7 
QFT result and IFN-毭 concentration by TLC, absolute lymphocyte count and lymphocyte percentage.      
Group n
Result[n(%)] Mean concentration 
(IU)Positive Negative
TLC groups(cells/毺L) <4 000 11 7(63.6) 4(36.4) 10.31
4 000-11 000 34 23(67.6) 11(32.4) 4.32
>11 000 35 29(82.9) 6(17.1) 7.90
Total 80 59(73.7) 21(26.3) 6.71
Significant level P = 0.255 P = 0.108
Absolute lymphocyte count (毺L) 900-4 500 42 33(78.6) 9(21.4) 8.03
>4 500 38 26(68.4) 12(31.6) 5.25
Total 80 59(73.7) 21(26.3) 6.71
Significant level          P =0.303 P =0.186
Lymphocyte( %) <20 31 21(67.7) 10(32.3) 5.24
20-45 29 24(82.8) 5(17.2) 7.71
>45 20 14(70.0) 6(30.0) 7.54
Total 80 59(73.7) 21(26.3) 6.71
Significant level P = 0.379 P = 0.054
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sensitivity & specificity of whole blood gamma interferon 
released following stimulation with PPD has been reported to 
be 96% and 98% for the diagnosis of TB[13].
  In the present study IFN-毭concentrations were 
significantly higher in patients with disease than healthy 
controls, as report of Vankayalapati et al[8]. Tsao et al[15] 
demonstrated high levels in BALF as compared to serum of 
active PMTB and they advocate IFN-毭estimation in BALF 
rather than serum in such cases, as PTB is a local disease 
and IFN-毭is secreted by local immune cells. Moreover, 
they observed that T-lymphocytes from BALF spontaneously 
secreted significantly greater quantities of IFN-毭as 
compared to those in peripheral blood. Some workers have 
determined a defect in peripheral blood lymphocytes from 
tubercular samples for IFN-毭production after stimulation 
with mitogens or antigens[21]. Together with reasons for 
depressed PPD induced IFN-毭production in PBMC of new TB 
patients (both HIV infected and no infected) in comparison 
to healthy controls viz: genetic defect in IFN-毭production / 
response, compartmentalization of antigen responsive cells 
to sites of active disease, active and selective depletion of 
circulating MTB responsive T cells during TB or increase 
in spontaneous and MTB induced programmed cell death 
among PBMC, it could also possibly explain the reason 
for low IFN-毭production or negative QFT result in our 
study. Inokuchi et al[17] observed phyto-hemagglutin (PHA) 
induced IFN-毭production to be significantly low in patients 
but no such difference with PPD induced IFN-毭. 
  All our patients were HIV sero-negative, however, in 
absence of TB HIV infection alone reduces IFN-毭production 
in response to antigens or mitogens. Tsiouris et al[18] 
observed significantly lower IFN-毭concentrations in HIV 
infected patients than in HIV negative patients with culture 
positive TB (P=0.033).
  Though the patients in age group <20 yrs in the present 
study showed highest positivity (92.3%), no significant 
change in sensitivity was observed with advance in age. 
Quantiferon TB Gold appears to function well in persons of 
all ages in report of Mori et al [23] on 110 culture confirmed 
TB patients stratified by age. A significant decline in test 
sensitivity was observed by them for the Mantoux test in 
contrast to QFT TB Gold, suggesting measurement of in 
vitro IFN-毭responses appropriate in the elderly. IFN-毭
concentrations were the lowest in age group 曒60 in our 
study, however these concentrations were not significant 
compared to other age groups, as reported by Sodhi et al [16] 
and Tsiouris et al[18].  
  MTB induced IFN-毭production was correlated with extent 
of disease, which was assessed either by the signs and 
symptoms of PTB, bacteriological grading (both smear and 
culture), radiographic extent of disease and hematological 
parameters viz. TLC, absolute lymphocyte count and 
lymphocyte percent.          
  With respect to signs & symptoms, QFT positivity and 
IFN-毭concentrations were more in patients with fever 
and weight loss while it was low in those with cough and 
haemoptysis, however, the differences were not significant 
when compared to those without them, suggesting that 
there was no correlation of IFN-毭response with signs and 
symptoms. Fever, weight loss, cough and haemoptysis are 
usually associated with more intensive disease, hence a 
higher IFN-毭response is expected in patients presenting 
with them. Tsao et al[15] reported significantly higher IFN-毭
levels in active TB patients with fever or loss of body weight, 
but they were observed in BALF and not serum. 
  Studies have reported that the severity of TB is associated 
with depression in lymphocytes and CD4
+ cell counts in 
HIV negative patients, a feature that could be due to either 
compartmentalization of antigen-responsive cells to sites 
of active MTB infection or active and selective depletion of 
circulating MTB responsive T cells during TB. This could 
result in unresponsiveness or poor response of the peripheral 
blood cells to produce IFN-毭, as both the number and 
function of lymphocytes can influence the amount of IFN-毭
production[17].  In the present study, not only normal and 
above normal lymphocyte count, lymphocyte percent and 
leukocyte count were observed in the active TB patients, 
but also the IFN-毭concentrations did not correlate with 
the counts, rather the IFN-毭concentrations were more in 
those with low leukocyte and absolute lymphocyte counts as 
compared to those having normal or above normal counts. 
Sodhi et al[16] also did not observe any correlation between 
IFN-毭concentrations with either absolute lymphocyte 
count or lymphocyte percent. Inokuchi et al[17] observed 
significantly lower total lymphocytes in active TB patients 
as compared to controls and reported that though the PHA 
induced IFN-毭per lymphocyte remained significantly lower 
(P<0.05) in patients than healthy volunteers, tuberculous 
PPD induced IFN-毭was not different between the two 
groups.  
  Understanding correlation of IFN-毭response with TB 
would be perfect, provided it is studied in active TB cases 
confirmed by a definite marker. There could be no less a 
perfect marker as a positive smear and/or culture for this 
and in addition the severity of PTB can be assessed through 
bacterial burden (smear and/or culture grading). Keeping this 
in mind we tried to find if the severity of disease, as assessed 
through smear or culture had any correlation with either QFT 
results or IFN-毭concentrations. This study didn't show any 
such correlation. We could not come across any studies in 
the literature that have looked into this type of correlation. 
However, a study on estimation of sensitivity of IFN-毭
in culture confirmed cases of TB has been done[23], which 
have shown the sensitivity of IFN-毭to be 89% against 66% 
by TST in such cases. Tsao et al[15] demonstrated highest 
IFN-毭levels in BALF of patients with higher bacterial load 
as assessed by smear and culture and have suggested that 
IFN-毭actually might be a marker of local inflammation 
and/or bacterial load in the lungs. Tsiouris et al[18] compared 
the sensitivity of QFT TB Gold kit, TST and sputum smear 
in diagnosis of culture confirmed cases of TB and found it 
to be 82%, 92% and 53% respectively in new PTB cases. 
Since they observed that the sensitivity of the TST combined 
with in tube IFN-毭estimation or sputum smear for AFB 
was high in PTB suspects (TST+QFT=96%, TST+ one sputum 
smear=93%), they are of the opinion that such combined 
testing strategy could be useful, in some settings, to exclude 
a diagnosis of PTB, considering the poor sensitivity of smear 
microscopy and specificity of TST. However, Inokuchi et al[17] 
did not find any correlation between PPD induced IFN-毭
and sputum smear.
  Sodhiratmadja et al[21] observed strong correlation of IFN-毭
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(PBMCs stimulated by M. tuberculosis) with radiographic 
extent of disease, both by univariate (P=0.0004) and 
multivariate (P=0.001) analysis in PTB HIV sero negatives 
patients only. On comparison with different degrees 
of disease extent, estimated by X ray, IFN-毭levels 
were significantly low (P=0.0001) in far advanced than 
moderately advanced in report of Dlugovitzky et al[14]. PPD 
induced IFN-毭in whole blood was found to be significantly 
low in far advanced disease (P<0.01) by Inokuchi et al [17]. 
Our study showed the same result, though the differences 
were not statistically significant. 
  In the present study mean IFN-毭levels were observed to 
be higher in patients presenting with cavity as compared 
to those without it. This is in contrast to that reported by 
Sodhi et al[16]. However, the differences in both were not 
significant. Moreover, the later measured IFN-毭released 
by PBMC's following stimulation with killed MTB, while our 
study measured it in whole blood following stimulation with 
TB specific antigens.  
  Sodhi et al [16] suggested that reduced MTB induced IFN-
毭production by PBMCs reflects disease severity. Tsao 
et al[15] regarded it as not only a marker of local inflammation 
but also bacterial load when measured in BALF. Inokuchi 
et al[17] found tuberculous PPD-IFN-毭/ PHA-IFN-毭a useful 
marker for TB diagnosis and reduced PHA- IFN-毭a marker 
of disease severity, while Tsiouris find IGRA plus TST useful 
in excluding the diagnosis of TB. 
  Though the IFN-毭concentrations is not correlated with any 
of the predictors of disease severity studied, the levels were 
found to be significantly higher in diseased as compared to 
healthy subjects. Considering the exorbitant cost of the kit 
(Rs 50 000/ per kit-44 tests), the study could be performed 
on limited patients only. To evaluate the correlation between 
disease severity and IFN-毭released by cells, further studies 
in larger population not only in whole blood but also in those 
from local site of infection need to be done.
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